Product logins

Find logins to all Clarivate products below.


Sjogren’s Syndrome | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016

Sjögren’s syndrome (SS) is an autoimmune disease characterized by dry eyes, dry mouth, and often also systemic manifestations such as fatigue and joint pain. While some SS cases are secondary, co-presenting with another, primary autoimmune disease, primary SS is the most common form. Current treatment of primary SS is mostly off-label and is focused on symptomatic relief of dry eyes, dry mouth, and/or systemic manifestations. Treatments that have a proven effect on autoimmune diseases other than SS have, for the large part, not demonstrated efficacy in SS, where the greatest unmet need remains for a single therapy that, likely by targeting an underlying disease process, could simultaneously address many of the syndrome’s signs and symptoms.

Related Market Assessment Reports

Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…